Sökning: id:"swepub:oai:lup.lub.lu.se:89dd3759-5a87-403a-96aa-308079027209" >
RHAPSODY, Biomarker...
RHAPSODY, Biomarkers and Novel Clinical Trial design in type 2 diabetes (T2D) and prediabetes
-
- Adams, Rachel (författare)
- Janssen UK
-
- Daly, Nicole (författare)
- Janssen UK
-
- Robertson, Elizabeth (författare)
- Diabetes UK
-
visa fler...
-
- Giordano, Giuseppe N. (författare)
- Lund University,Lunds universitet,Genetisk och molekylär epidemiologi,Forskargrupper vid Lunds universitet,Genetic and Molecular Epidemiology,Lund University Research Groups,Skåne University Hospital
-
visa färre...
-
(creator_code:org_t)
- 2020-12-06
- 2021
- Engelska.
-
Ingår i: Endocrinology, Diabetes and Metabolism. - : Wiley. - 2398-9238. ; 4:2
- Relaterad länk:
-
http://dx.doi.org/10... (free)
-
visa fler...
-
https://onlinelibrar...
-
https://lup.lub.lu.s...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Developing a novel therapeutic product for the treatment of type 2 diabetes (T2D) is a long, resource-intensive process. Novel biomarkers could potentially aid clinical trial design by shortening clinical trials or enabling better prediction of at-risk populations and/or disease progression. Novel clinical trial designs could lead to reduced costs of development and less burden to patients, due to shorter trial duration, and/or less burdensome assessments.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Endokrinologi och diabetes (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Endocrinology and Diabetes (hsv//eng)
Nyckelord
- biomarkers
- disease progression
- novel clinical trial design
- prediabetes
- type 2 diabetes mellitus
Publikations- och innehållstyp
- art (ämneskategori)
- ref (ämneskategori)
Hitta via bibliotek
Till lärosätets databas